25O - International comparison of treatment and survival for pleural mesothelioma, combined analysis of 9.014 patients from Belgium, the Netherlands and E...
|Date||28 March 2014|
|Session||Proffered papers 3 - Screening, staging and epidemiology|
|Topics|| Cancer Aetiology, Epidemiology, Prevention
|Presenter||Jan van Meerbeeck|
|Citation||Journal of Thoracic Oncology (2014) 9 (Supplement 9): S7-S52. 10.1097/JTO.0000000000000131|
J.P. van Meerbeeck1, R.A. Damhuis2, A. Khakwani3, H. De Schutter4, A. Rich3, S.A. Burgers5
Pleural mesothelioma is refractory to treatment and has a poor prognosis. Only chemotherapy was proven effective in randomized trials. Novel chemotherapy may increase median survival by several months and was gradually introduced in the period 2003–2006. Little is known about contemporary treatment practice in Europe. To determine patterns of care and current survival rates, three large population-based registries were queried in a uniform manner.